高血压左心室肥厚患者血浆中自噬相关蛋白9a的水平及其临床意义

doi:10.13481/j.1671-587x.20180417

摘要/Abstract

摘要： 目的：探讨高血压左心室肥厚（LVH）患者血浆中自噬相关蛋白9a （ATG9a）水平与舒张期末室间隔厚度（IVSd）和舒张期末左心室后壁厚度（LVPWd）的关系，进一步评估其对高血压患者LVH的临床预测作用。方法：高血压住院患者128例，根据心脏彩色超声结果分为LVH组66例和非LVH组62例。采用酶联免疫吸附测定（ELISA）法检测患者血浆中ATG9a水平，分析高血压LVH患者血浆ATG9a水平与IVSd和LVPWd的相关性，并计算受试者工作特征（ROC）曲线下面积（AUC）。结果：高血压LVH组患者血浆中ATG9a水平高于非LVH组（P<0.05）；高血压LVH患者血浆中ATG9a平均水平与患者IVSd和LVPWd均呈正相关关系（r=0.774，P<0.01；r=0.685，P<0.01）；测定高血压LVH患者血浆ATG9a水平的AUC为0.976（95％CI：0.923~0.996），预测高血压LVH的最佳临界值为1.69 μg·L^-1，其敏感度和特异度分别为96.8%和90.6%。结论：血浆ATG9a可能作为自噬诱导因子参与心肌肥厚的发病。血浆ATG9a水平与高血压LVH患者室壁厚度呈正相关关系，血浆ATG9a水平可预测高血压患者LVH。

Abstract: Objective:To explore the relationships between the levels of autophagy-related protein 9a (ATG9a) in the plasma and the end-diastolic interventricular septum dimension(IVSd) and left ventricular posterior wall dimension (LVPWd) in the hypertension patients with left ventricular hypertrophy (LVH),and to further evaluate its effect in clinical prediction for the hypertension patients with LVH. Methods: One hundred and twenty-eight hypertension patients in hospital were enrolled.According to the results of cardiac echocardiography,all enrolled patients were divided into LVH group (n=66) and non-LVH group (n=62).The levels of plasma ATG9a in the patients ware detected by enzyme linked immunosorbent assay (ELISA).The levels of plasma ATG9a of the patients in LVH group and non-LVH group were compared.The correlations between the levels of plasma ATG9a and IVSd or LVPWd in the hypertension patients with LVH were further analyzed.And the area under receiver operating characteristic curve (AUC) of plasma ATG9a level was calculated. Results:The plasma ATG9a level of the hypertension patients in LVH group was higher than that in non-LVH group (P<0.05).The plasma ATG9a level in the patients with LVH showed significantly positive correlations with IVSd and LVPWd(r=0.774,r=0.685,P<0.01). The AUC for plasma ATG9a level was 0.976(95%CI:0.923-0.996).The optimal cut-off value of plasma ATG9a level for ROC curve was 1.69 μg·L^-1,the sensitivity and specificity were 96.8% and 90.6%,respectively. Conclusion:The plasma ATG9a may play an important role in the pathogenesis of myocardial hypertrophy as autophagy-induced factor. The level of plasma ATG9a has positive correlation with IVSd and LVPWd in the hypertension patients with LVH. The level of plasma ATG9a may predict the LVH in the hypertension patients.

Key words: autophagy-related protein-9a, left ventricular hypertrophy, interventricalar septum dimension, hypertension, left ventricular posterior wall dimension

中图分类号:

R541.3

谢文杰, 龙海权, 宋代富, 区德锦, 江岚, 陈晞明, 黄炯华. 高血压左心室肥厚患者血浆中自噬相关蛋白9a的水平及其临床意义[J]. 吉林大学学报(医学版), 2018, 44(04): 786-790.

XIE Wenjie, LONG Haiquan, SONG Daifu, OU Dejin, JIANG Lan, CHEN Ximing, HUANG Jionghua. Level of autophagy-related protein-9a in plasma of hypertension patients with left ventricular hypertrophy and its clinical significance[J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 786-790.

参考文献

[1] Okwuosa TM,Soliman EZ,Lopez F,et al. Left ventricular hypertrophy and cardiovascular disease risk prediction and reclassification in blacks and whites:the Atherosclerosis Risk in Communities Study[J].Am Heart J,2015,169(1):155-161.
[2] Yang LY,Ge X,Wang YL,et al.Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients:a meta-analysis[J].Am J Med Sci,2013,345(1):1-9.
[3] Verdecchia P,Gentile G,Angeli F,et al.Beyond blood pressure:evidence for cardiovascular,cerebrovascular,and renal protective effects of renin-angiotensin system blockers[J].Ther Adv Cardiovasc Dis,2012,6(2):81-91.
[4] Xing F,Chen J,Zhao B,et al.Real role of beta-blockers in regression of left ventricular mass in hypertension patients:Bayesian network meta-analysis[J].Medicine(Baltimore),2017,96(10):e6290.
[5] Huang JH,Sun W,Huang H,et al.miR-34a modulates angiotensin Ⅱ-induced myocardial hypertrophy by direct inhibition of ATG9A expression and autophagic activity[J].PLoS One,2014,9(4):e94382.
[6] Huang JH,Huang H,Pan W,et al.Renal denervation attenuates cardiac hypertrophy in spontaneously hypertensive rats via regulation of autophagy[J].Mol Med Rep,2017,16(2):2023-2029.
[7] Nishida K,Otsu K.Autophagy during cardiac remodeling[J].J Mol Cell Cardiol,2016,95:11-18.
[8] Schiattarella GG,Hill JA.Therapeutic targeting of autophagy in cardiovascular disease[J].J Mol Cell Cardiol,2016,95:86-93.
[9] Lin C,Liu Z,Lu Y,et al.Cardioprotective effect of salvianolic acid b on acute myocardial infarction by promoting autophagy and neovascularization and inhibiting apoptosis[J].J Pharm Pharmacol,2016,68(7):941-952.
[10] Muhammad E,Levitas A,Singh SR,et al.Plekhm2 mutation leads to abnormal localization of lysosomes,impaired autophagy flux and associates with recessive dilated cardiomyopathy and left ventricular noncompaction[J].Hum Mol Genetics,2015,24(25):7227-7240.
[11] Mesquita A,Cardenal-Munoz E,Dominguez E,et al.Autophagy in dictyostelium:Mechanisms,regulation and disease in a simple biomedical model[J].Autophagy,2017,13(1):24-40.
[12] Li MH,Zhang YJ,Yu YH,et al.Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy[J].Eur J Pharmacol,2014,728:67-76.
[13] Qin Q,Qu C,Niu T,et al.Nrf2-mediated cardiac maladaptive remodeling and dysfunction in a setting of autophagy insufficiency[J].Hypertension,2016,67(1):107-117.
[14] Li J,Cai Y.The dual effects of autophagy in myocardial hypertrophy[J].Acta Cardiol,2015,70(4):493-498.
[15] Shimizu I,Minamino T.Physiological and pathological cardiac hypertrophy[J].Mol Cell Cardiol,2016,97:245-262.
[16] Suzuki SW,Yamamoto H,Oikawa Y,et al.Atg13 HORMA domain recruits Atg9 vesicles during autophagosome formation[J].Proc Natl Acad Sci USA,2015,112(11):3350-3355.
[17] Kakuta S,Yamaguchi J,Suzuki C,et al.Small gtpase rab1b is associated with atg9a vesicles and regulates autophagosome formation[J].FASEB J,2017,31(9):3757-3773.
[18] Haring B,Omidpanah A,Suchy-Dicey AM,et al.Left ventricular mass,brain magnetic resonance imaging,and cognitive performance:Results from the strong heart study[J].Hypertension,2017,70(5):964-971.
[19] Rider OJ,Ntusi N,Bull SC,et al.Improvements in ECG accuracy for diagnosis of left ventricular hypertrophy in obesity[J].Heart,2016,102(19):1566-1572.
[20] Lu N,Zhu JX,Yang PX,et al.Models for improved diagnosis of left ventricular hypertrophy based on conventional electrocardiographic criteria[J].BMC Cardiovasc Disord,2017,17(1):217.